Immediate-Onset Acute Pancreatitis During Transarterial Chemoembolization: A Case Report.
Transarterial chemoembolization (TACE) is widely used in treating unresectable hepatocellular carcinoma (HCC), while acute pancreatitis represents a rare but serious complication of this procedure.
APA
Shen Y, Deng X, et al. (2025). Immediate-Onset Acute Pancreatitis During Transarterial Chemoembolization: A Case Report.. Cureus, 17(11), e96400. https://doi.org/10.7759/cureus.96400
MLA
Shen Y, et al.. "Immediate-Onset Acute Pancreatitis During Transarterial Chemoembolization: A Case Report.." Cureus, vol. 17, no. 11, 2025, pp. e96400.
PMID
41376762
Abstract
Transarterial chemoembolization (TACE) is widely used in treating unresectable hepatocellular carcinoma (HCC), while acute pancreatitis represents a rare but serious complication of this procedure. This article reports the case of a 57-year-old male with hepatitis B-related liver cirrhosis and China Liver Cancer stage IIb HCC who experienced the abrupt onset of acute pancreatitis during the TACE procedure, immediately following the embolic infusion. By reviewing the patient's clinical presentation, imaging data, laboratory findings, and treatment process, we infer that the acute pancreatitis was most likely caused by the reflux of embolic material, leading to pancreatic ischemia. This report focuses on the clinical features, underlying mechanisms, and prevention strategies of acute pancreatitis complicating TACE procedures.
같은 제1저자의 인용 많은 논문 (5)
- Histone H3K4 monomethyltransferase SETD7 promoted osteogenic differentiation of bone marrow mesenchymal stem cells exposed to Hydroquinone via autophagy.
- Development of an UPLC-MS/MS method for quantification of donafenib and its metabolite in rat plasma: application to drug-drug interaction.
- Effects of Cytochrome P450 enzymes and drug-drug interaction on donafenib metabolism: in vivo, in vitro and in silico.
- Virtual multiplex staining of the pancreatic islets across type 1 diabetes progression using a Schrödinger bridge.
- PLAGL2 promotes HCC progression by recruiting tumour-associated macrophages via CCL2/CCR2 signalling.